Role of heme-hemopexin in human T-lymphocyte proliferation.
Heme-hemopexin supports and stimulates proliferation of human acute T-lymphoblastic (MOLT-3) cells, suggesting the participation of heme in cell growth and division. MOLT-3 cells express approximately 58,000 hemopexin receptors per cell (apparent Kd 20 nM), of which about 20% are on the cell surface. Binding is dose- and temperature-dependent, and growth in serum-free IMDM medium is stimulated by 100-1000 nM heme-hemopexin, consistent with the high affinity of the receptor for hemopexin, and maximal growth is seen in response to 500 nM complex. Growth was similar in defined minimal medium supplemented with either low concentrations of heme-hemopexin or iron-transferrin, and either of these complexes were about 80% as effective as a serum supplement. Heme-hemopexin, but not apo-hemopexin, reversed the growth inhibition caused by desferrioxamine showing that heme-iron derived from heme catabolism is used for cell growth. Cobalt-protoporphyrin (CoPP)-hemopexin, which binds to the receptor but is not transported intracellularly [Smith et al., (1993) J. Biol. Chem. 268, 7365], also stimulated cell proliferation in serum-free IMDM but did not "rescue" the cells from desferrioxamine. Furthermore, CoPP-hemopexin effectively competed for the hemopexin receptor with heme-hemopexin and diminished its growth stimulatory effects. In addition, protein kinase C (PKC) is translocated to the plasma membrane within 5 min after heme-hemopexin is added to the medium, reaches maximum activity within 5-10 min, and declines to unstimulated levels by 30 min. Heme-hemopexin and CoPP-hemopexin both augmented MOLT-3 cell growth stimulated by serum. Thus, heme-hemopexin not only functions as an iron source for T-cells but occupancy of the hemopexin receptor itself triggers signaling pathway(s) involved in the regulation of cell growth. The stimulation of growth of human T-lymphocytes by heme-hemopexin is likely to be a physiologically relevant mechanism at sites of injury, infection, and inflammation.
Smith
A
A
Division of Molecular Biology and Biochemistry, School of Biological Sciences, University of Missouri-Kansas City 64110-2499, USA. annsmith@cctr.umkc.edu
Eskew
J D
JD
Borza
C M
CM
Pendrak
M
M
Hunt
R C
RC
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003676:Deferoxamine / Q000494:pharmacology; D006418:Heme / Q000494:pharmacology / Q000502:physiology*; D006466:Hemopexin / Q000494:pharmacology / Q000502:physiology*; D006801:Humans; D007501:Iron / Q000502:physiology; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000473:pathology*; D051379:Mice; D009363:Neoplasm Proteins / Q000187:drug effects / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D011524:Protoporphyrins / Q000494:pharmacology; D018000:Receptors, Peptide / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects* / Q000473:pathology; D014407:Tumor Cells, Cultured
D009363:Neoplasm Proteins; D011524:Protoporphyrins; D018000:Receptors, Peptide; C047453:hemopexin receptor; D006418:Heme; C007095:cobaltiprotoporphyrin; D006466:Hemopexin; D007501:Iron; D011493:Protein Kinase C; D003676:Deferoxamine